Hycells’s Selected PBMC Reconstruction Data Presentation (Part 1)
Release Date:
2026-06-22 11:45
Experimental Background and Objectives
The humanized PBMC-CDX model is an essential tool for in vivo efficacy evaluation of tumor immunotherapy agents. However, significant inter‑donor variability exists in the engraftment efficiency, T‑cell subset differentiation, and the risk of graft‑versus‑host disease (GVHD) among different PBMC donors, which directly impacts model stability and the experimental window.
The objective of this study In the NOG mouse model, we systematically evaluated the in vivo immune reconstitution profiles of multiple PBMC donors and established data-driven donor selection criteria, thereby providing predictable and reproducible cellular resources for tumor immunology research.
Experimental Design
In vivo immune reconstitution dynamics
Data Filtering and Display
1. Human CD45+ cell engraftment rate (hCD45+%)
Key Findings:
G4 achieved the fastest engraftment and the highest peak (reaching 81.3% on Day 22), but was accompanied by severe GVHD.
G1, G5, and G6 have achieved stable reconstruction, with values remaining between 55% and 78% from Day 22 to Day 28, making them suitable for long-term monitoring.
2. Dynamics of T-cell subsets: CD4/CD8 ratio
Key Findings:
G3, G4, G5, and G6 exhibit CD8+ T-cell dominance after Day 22, which is more conducive to studies of anti-tumor immunity.
G1 and G2 maintain a CD4+ predominance, making them suitable for studies of CD4+ T cell–related mechanisms.
GVHD and Animal Tolerance
1. Dynamic (mean) of GVHD scores
2. Changes in Body Weight and Tolerability
G1, G5, G6 : Body weight remained stable or decreased slightly (<10%) prior to Day 28, with good tolerability.
G4 : Day 14—Body weight continued to decline; from Day 22 to Day 28, some animals exhibited a weight loss exceeding 20%, accompanied by high GVHD scores.
G3 : On Day 28, some animals exhibited a marked weight loss, consistent with severe GVHD.
Donor Comprehensive Rating and Recommendation
Donor suitability exhibits substantial interindividual variability: the rate of immune reconstitution, the timing and severity of graft-versus-host disease (GVHD), and the direction of T-cell subset shifts are all strongly correlated with donor characteristics.
High engraftment does not equate to high availability: Although G4 exhibits the highest engraftment rate, severe graft-versus-host disease (GVHD) markedly shortens the experimental window, rendering it unsuitable for long-term studies.
Preferred donor recommendations: G5 (W054K133) and G6 (W054K149) demonstrate the best overall performance in terms of reconstitution efficiency, CD8‑dominant repertoire, and tolerability, making them suitable for tumor immunotherapy efficacy studies.
Hycells Biology Differentiated Advantages of PBMC Preferred Services
Multidimensional in vivo validation: Each batch of PBMCs has been rigorously tested in immunodeficient mice, with comprehensive data provided, including reconstitution curves, GVHD scores, and subpopulation dynamics.
The donor database continues to expand: Covering health donors from multiple countries, providing HLA typing , viral screening, in vitro immunophenotyping, and other background information.
Customized Matching: We recommend the most suitable donor based on the customer’s research needs (long-term vs. short-term, CD4/CD8 preference, and low GVHD risk requirements).
Data transparency and traceability: Provide Streaming raw data , body weight records, GVHD scoring sheets, and medication administration logs, to ensure experimental reproducibility.
For access to the complete experimental report—including raw flow cytometry data, body weight records, GVHD scoring tables, and dosing logs—or for customized donor screening services, please contact the Hycells Biotechnology team.
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board